Turning Point Therapeutics (NASDAQ:TPTX) insider Jingrong Jean Cui sold 18,500 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $57.68, for a total transaction of $1,067,080.00. Following the transaction, the insider now owns 1,301,298 shares of the company’s stock, valued at approximately $75,058,868.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jingrong Jean Cui also recently made the following trade(s):

  • On Monday, January 13th, Jingrong Jean Cui sold 18,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $52.87, for a total transaction of $978,095.00.
  • On Friday, December 20th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $63.40, for a total transaction of $729,100.00.
  • On Wednesday, December 18th, Jingrong Jean Cui sold 18,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $59.20, for a total transaction of $1,095,200.00.
  • On Monday, December 16th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $58.35, for a total transaction of $671,025.00.
  • On Friday, December 13th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $55.75, for a total transaction of $641,125.00.
  • On Wednesday, December 11th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $52.94, for a total transaction of $608,810.00.
  • On Monday, December 9th, Jingrong Jean Cui sold 11,500 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $55.32, for a total transaction of $636,180.00.
  • On Thursday, December 5th, Jingrong Jean Cui sold 56,110 shares of Turning Point Therapeutics stock. The stock was sold at an average price of $51.95, for a total transaction of $2,914,914.50.

TPTX stock traded up $0.82 during trading hours on Tuesday, reaching $53.83. The stock had a trading volume of 456,391 shares, compared to its average volume of 519,943. The company has a debt-to-equity ratio of 0.01, a quick ratio of 36.64 and a current ratio of 36.64. The stock has a 50-day simple moving average of $58.25 and a 200 day simple moving average of $46.59. Turning Point Therapeutics has a fifty-two week low of $24.21 and a fifty-two week high of $67.54.

Turning Point Therapeutics (NASDAQ:TPTX) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.04). As a group, equities analysts predict that Turning Point Therapeutics will post -3.08 EPS for the current year.

Several research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Turning Point Therapeutics from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a report on Friday, November 8th. Roth Capital assumed coverage on shares of Turning Point Therapeutics in a report on Thursday, November 14th. They set a “buy” rating and a $65.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Turning Point Therapeutics in a report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a buy rating, Turning Point Therapeutics has a consensus rating of “Buy” and an average price target of $55.00.

Hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in Turning Point Therapeutics in the second quarter valued at $25,000. Wells Fargo & Company MN acquired a new stake in Turning Point Therapeutics in the second quarter valued at $72,000. JPMorgan Chase & Co. acquired a new stake in Turning Point Therapeutics in the second quarter valued at $71,000. Cubist Systematic Strategies LLC acquired a new stake in Turning Point Therapeutics in the second quarter valued at $90,000. Finally, FNY Investment Advisers LLC acquired a new stake in Turning Point Therapeutics in the third quarter valued at $118,000. Hedge funds and other institutional investors own 66.79% of the company’s stock.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

See Also: What is quantitative easing?

Insider Buying and Selling by Quarter for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.